Our Pricing

Ozempic vs Mounjaro UK Prescription

When comparing ozempic vs mounjaro uk prescription options, understanding the clinical differences between these two treatments is essential for making an informed choice. Both are injectable medications licensed by the MHRA for weight management, but they work through different mechanisms and produce distinct clinical outcomes. At Cured Pharmacy, our UK-registered prescribers assess your individual circumstances to determine which treatment may be most suitable, with transparent pricing and discreet delivery across the UK.

Ozempic vs Mounjaro: Understanding the Key Differences

Ozempic contains semaglutide, a GLP-1 receptor agonist that mimics a single natural hormone involved in appetite regulation and blood sugar control [1]. Mounjaro, by contrast, contains tirzepatide — the first dual GIP/GLP-1 receptor agonist licensed in the UK, activating two complementary pathways simultaneously [2]. This dual mechanism is what sets Mounjaro apart from Ozempic and other single-pathway treatments.

In head-to-head clinical trials, tirzepatide demonstrated superior weight loss outcomes compared to semaglutide. The SURPASS-2 trial showed that patients taking the highest dose of Mounjaro achieved an average weight reduction of 15.7 kg over 40 weeks, compared to 5.7 kg with semaglutide 1 mg [2]. These results suggest that the dual receptor approach may offer enhanced efficacy for eligible patients, though individual responses vary considerably.

Both medications are administered as once-weekly subcutaneous injections using pre-filled pens. Ozempic is available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses, whilst Mounjaro offers a broader dose range from 2.5 mg up to 15 mg, allowing for more granular titration [1][2]. Your UK prescriber will determine the appropriate starting dose and escalation schedule based on your medical history, current medications, and treatment response.

How Mounjaro Works: The Dual Receptor Advantage

Tirzepatide's dual action targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. GIP enhances insulin secretion and may influence fat metabolism, whilst GLP-1 slows gastric emptying, reduces appetite, and improves glycaemic control [3]. This combined approach produces more pronounced effects on satiety and energy expenditure than GLP-1 activation alone.

Clinical trial data from the SURPASS programme demonstrates this advantage clearly. In SURPASS-3, participants taking the 15 mg dose of Mounjaro achieved an average body weight reduction of 22.5% over 72 weeks — significantly higher than outcomes typically observed with semaglutide-based treatments [3]. These results positioned tirzepatide as one of the most effective pharmacological weight management options currently available in the UK.

The medication works by reducing hunger signals, increasing feelings of fullness after meals, and slowing the rate at which food leaves your stomach. Patients often report decreased food cravings and smaller portion sizes within the first few weeks of treatment, though individual experiences vary. Mounjaro is most effective when combined with a reduced-calorie diet and increased physical activity, as recommended by NICE guidelines for weight management [4].

Expected Timeline and Results

Most patients begin to notice appetite changes within the first 1-2 weeks of starting Mounjaro, with measurable weight loss typically evident by week 4. The treatment follows a gradual dose escalation protocol, starting at 2.5 mg and increasing every four weeks as tolerated, which helps minimise gastrointestinal side effects whilst optimising efficacy. Maximum weight loss is generally achieved between 52 and 72 weeks of continuous treatment, subject to individual response and adherence [3].

How Ozempic Works for Weight Management

Ozempic activates GLP-1 receptors in the brain, pancreas, and gastrointestinal tract, producing multiple metabolic effects that support weight reduction. The medication slows gastric emptying, which prolongs feelings of fullness after eating, and acts on appetite centres in the hypothalamus to reduce hunger signals [1]. It also enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release.

The STEP trials, which evaluated semaglutide at higher doses than typically used in Ozempic, demonstrated average weight reductions of 14.9% over 68 weeks in participants without diabetes [5]. Whilst Ozempic is primarily licensed for type 2 diabetes management in the UK, it is sometimes prescribed off-label for weight management when other treatments are unsuitable, subject to prescriber discretion and clinical assessment.

Ozempic follows a similar dose escalation pattern to Mounjaro, beginning at 0.25 mg weekly and increasing gradually to minimise side effects. The standard maintenance dose for weight management is 1 mg weekly, though some prescribers may increase to 2 mg for patients who tolerate the medication well and require additional efficacy. As with all GLP-1 treatments, Ozempic is most effective when combined with lifestyle modifications including dietary changes and regular physical activity [1][5].

Ozempic vs Mounjaro: Side Effects and Tolerability

Both medications share similar side effect profiles, with gastrointestinal symptoms being the most commonly reported. Nausea, diarrhoea, constipation, vomiting, and abdominal discomfort affect a significant proportion of patients, particularly during dose escalation phases [2][3]. These effects are generally mild to moderate and tend to diminish over time as your body adjusts to the medication.

Clinical trial data suggests that gastrointestinal side effects may be slightly more frequent with tirzepatide compared to semaglutide, though discontinuation rates due to adverse events remain relatively low for both treatments. In SURPASS-2, approximately 6% of participants discontinued Mounjaro due to adverse events, compared to 3% in the semaglutide group [2]. However, the higher efficacy of tirzepatide may justify the marginally increased side effect burden for many patients.

More serious but rare side effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly when used alongside other glucose-lowering medications). Both Ozempic and Mounjaro carry warnings about potential thyroid C-cell tumours based on animal studies, though no causal relationship has been established in humans [1][3]. Your UK prescriber will review your complete medical history to identify any contraindications before prescribing either medication.

Managing Common Side Effects

To minimise gastrointestinal symptoms, eat smaller, more frequent meals and avoid high-fat foods during the initial weeks of treatment. Staying well-hydrated and avoiding lying down immediately after eating can help reduce nausea. If side effects become troublesome, your prescriber may adjust your dose escalation schedule or recommend symptomatic treatments. Never adjust your dose without consulting your healthcare provider, as proper titration is essential for both efficacy and tolerability.

Mounjaro vs Ozempic UK: Pricing and Availability

At Cured Pharmacy, Mounjaro is available from £135.00 per month, with final pricing dependent on your prescribed dose following clinical assessment by a UK-registered prescriber. We guarantee the lowest prices in the UK for genuine, MHRA-licensed medications, with transparent upfront pricing displayed before you complete your consultation. All prices include the cost of your medication, prescriber review, and discreet delivery to your UK address.

Ozempic is not currently stocked at Cured Pharmacy due to ongoing supply constraints affecting the UK market. However, we offer Wegovy — which contains the same active ingredient as Ozempic (semaglutide) but at doses specifically optimised for weight management — as an alternative. Wegovy provides comparable clinical benefits to Ozempic for weight loss and may be more suitable for patients whose primary goal is weight management rather than diabetes control.

For patients seeking the most cost-effective GLP-1 treatment, Wegovy represents excellent value whilst delivering clinically proven weight loss outcomes. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), and our team of UK prescribers ensure that every patient receives personalised treatment recommendations based on their individual circumstances, medical history, and treatment goals. All prescription medications require completion of a free online consultation, which typically takes under three minutes.

Getting Your Ozempic vs Mounjaro UK Prescription with Cured Pharmacy

Starting treatment with Cured Pharmacy is straightforward and discreet. Begin by completing our free online medical consultation, which asks about your weight history, current medications, medical conditions, and treatment goals. A UK-registered prescriber will review your responses, typically within 24 hours, and determine whether Mounjaro, Wegovy, or an alternative weight management treatment is appropriate for your circumstances.

If approved, your prescription is sent electronically to our UK-registered pharmacy (GPhC 9012511), where your medication is dispensed and prepared for delivery. We use 100% discreet packaging with no external branding or indication of contents, and all orders are dispatched via tracked courier for security and peace of mind. Most patients receive their medication within 2-3 working days of prescription approval.

Ongoing support is available throughout your treatment journey. If you experience side effects, have questions about dose escalation, or need to adjust your treatment plan, our clinical team is available by phone on (+44) 116 4646009 during business hours. We also offer convenient repeat prescription services, ensuring you never run out of medication and can maintain consistent treatment without interruption.

What to Expect During Your Consultation

Our online consultation covers essential safety questions including your BMI, previous weight loss attempts, cardiovascular history, and current medications. Be honest and thorough in your responses, as this information helps your prescriber make safe, appropriate treatment decisions. If your prescriber determines that Mounjaro or other injectable treatments are not suitable, they may recommend alternative options such as Orlistat or lifestyle interventions. Your safety is always our priority, and not every patient will be suitable for GLP-1 therapy.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189
5. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.